Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P51532 (
transcriptional activator
)
6,546
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The intensity and duration of activation of a signal transduction system are important determinants of the specificity of the cellular response to the stimulus. It is unclear how different cells can generate a signal of varying intensity and duration in response to the same cytokine. We investigated the role of the
transcriptional activator
and Smad1/4 cofactor
OAZ
in regulating bone morphogenetic protein (BMP) signaling. We demonstrate that upon BMP4 stimulation, an
OAZ
-Smad1/4 complex binds to and activates the gene encoding Smad6, a specific inhibitor of the BMP pathway. Removal of endogenous
OAZ
from pluripotent embryonal carcinoma cells prevents the induction of Smad6 by BMP4 and extends the period of detection of phosphorylated Smad1 after BMP stimulation. Conversely, in cells that do not normally express
OAZ
, such as myoblasts and smooth muscle cells, forced
OAZ
expression leads to faster and higher Smad6 induction in response to BMP4, decrease of Smad1 phosphorylation, and attenuation of BMP-mediated responses. Our results demonstrate that
OAZ
can alter the intensity and duration of the BMP stimulus through Smad6 and indicate that the tissue-specific expression of
OAZ
is a critical determinant of the cellular response to the BMP signal.
...
PMID:OAZ regulates bone morphogenetic protein signaling through Smad6 activation. 1637 39